Phase 2 Completed N=56 Randomized Quadruple-blind Treatment

American Ginseng Treatment for Multiple Sclerosis Related Fatigue

Multiple Sclerosis

Source: ClinicalTrials.gov NCT00754832 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Jan 2012

Primary outcomePrimary: Fatigue Severity Scale — 5.5; 5.5 units on a scale

Summary

This research project will determine the safety and tolerability of ginseng in subjects with MS and will gather preliminary data on the efficacy of ginseng vs placebo for the treatment of MS fatigue.

Outcome Measures

Outcome	Result	p-value
PRIMARY Fatigue Severity Scale	5.5; 5.5	—
SECONDARY Modified Fatigue Impact Scale	42.7; 43.7	—
SECONDARY Realtime Digital Fatigue Score	4.2; 4.2	—

Eligibility Criteria

Inclusion Criteria

MS as diagnosed by the McDonald criteria
Complaint of fatigue that has been persistent for at least 2 months
FSS score of 4 or greater;
Age 18-70.

Exclusion Criteria

Use of ginseng or stimulants in the prior 6 weeks
Acute treatment with glucocorticoids in the prior 6 weeks
BDI >31
Significant MS exacerbation in prior 30 days
Diabetes
Uncontrolled hypertension
Other serious medical disease, pregnancy or breastfeeding
Breast disease
Abnormal bleeding or clotting disorder
Current use of warfarin, albendazole, nifedipine, digoxin, bumetadine, selegiline, isocarboxazid, or phenelzine
Current use of lasix for poorly controlled hypertension or congestive heart failure
Current drug or alcohol abuse; inability to complete the self report forms

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00754832). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.